All In Biotech

Drug Trial Radar · NCT03614494

Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception

Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception: Randomised Controlled Trial

Last checked: Nov 19, 2026Latest source record: May 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 860 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

860

Actual

Start

Aug 20, 2018

Primary completion

Oct 5, 2022

Study completion Oct 5, 2022

Sponsor

Lead sponsor
Dr. Hang Wun Raymond LiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Family Planning Association of Hong Kong
First posted
Aug 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomised controlled trial aimed at comparing the efficacy of levonorgestrel (LNG) co-administered with piroxicam or placebo for oral emergency contraception (EC). Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a pain-killer in inflammatory conditions. Efficacy will be measured as the percentage of pregnancies prevented.

Conditions

  • Emergency Contraception

Interventions

  • Piroxicam 40 mgDrug

    Additional co-treatment

  • Levonorgestrel 1.5mgDrug

    Standard treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Pregnancies PreventedTime frame: 1 month

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • The Family Planning Association of Hong Kong

    Hong Kong, Hong Kong

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.